Cargando…
The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder
OBJECTIVE: The prevalence and clinically associated factors of hyperuricemia (HUA) have been widely studied in the general population but rarely in patients with bipolar disorder (BPD) co-morbid with HUA. This study attempted to investigate the prevalence of HUA in BPD patients and analyze the assoc...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523783/ https://www.ncbi.nlm.nih.gov/pubmed/36188459 http://dx.doi.org/10.3389/fnins.2022.998747 |
_version_ | 1784800362173038592 |
---|---|
author | Li, Shuyun Lu, Xiaobing Chen, Xiaodong Huang, Zebin Zhou, Hui Li, Zezhi Ning, Yuping |
author_facet | Li, Shuyun Lu, Xiaobing Chen, Xiaodong Huang, Zebin Zhou, Hui Li, Zezhi Ning, Yuping |
author_sort | Li, Shuyun |
collection | PubMed |
description | OBJECTIVE: The prevalence and clinically associated factors of hyperuricemia (HUA) have been widely studied in the general population but rarely in patients with bipolar disorder (BPD) co-morbid with HUA. This study attempted to investigate the prevalence of HUA in BPD patients and analyze the associated correlates of HUA. MATERIALS AND METHODS: In this study, 182 outpatients with BPD and 182 healthy controls participated. The demographic and clinical information were collected. The body weight, height, waist circumference (WC), hip circumference (HC), and blood pressure (BP) were measured. The levels of serum uric acid (UA), triglyceride (TG), high-density lipoprotein (HDL-C), and fasting blood glucose (FBG) were also determined. RESULTS: BPD patients had a significantly higher prevalence of HUA (40.7%) compared to healthy controls (30.2%) (χ(2) = 4.335, P = 0.037). The systolic blood pressure (SBP), pulse pressure (PP), FBG, UA, and body mass index (BMI) were higher in the BPD group compared with those in the control group, while the diastolic blood pressure (DBP) and HDL-C level were lower (P < 0.05) in BPD patients. The prevalence of HUA was higher in BPD patients who used antipsychotics combined with mood stabilizers than that in BPD subjects receiving the mood stabilizers alone (P < 0.001). The prevalence of HUA and increased serum UA levels were higher in the manic group (62.1%) than in the depressive (34.3%) or euthymia group (17.0%) (P < 0.001). Additionally, the severity of mania was positively correlated with the UA level (r = 0.410, P < 0.001). There were significant differences in terms of MetS (29.7% vs. 14.8%), BMI, HC, WC, TG, and HDL-C between the HUA and the non-HUA groups (P < 0.05). The unconditional logistic regression analysis revealed that high BMI (OR = 1.210; 95%CI: 1.100–1.331) and high TG level (OR = 1.652; 95%CI: 1.058–2.580) were the major risk factorids for HUA in BPD patients. CONCLUSION: Our study suggests that patients with BPD are prone to metabolic diseases such as HUA. Higher serum levels of TG and high BMI could be associated with HUA development. Clinicians need to regularly monitor and evaluate BPD patients for their serum UA levels, especially for BPD patients with manic/hypomanic episodes and/or under the treatment of antipsychotics combined with mood stabilizers. |
format | Online Article Text |
id | pubmed-9523783 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95237832022-10-01 The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder Li, Shuyun Lu, Xiaobing Chen, Xiaodong Huang, Zebin Zhou, Hui Li, Zezhi Ning, Yuping Front Neurosci Neuroscience OBJECTIVE: The prevalence and clinically associated factors of hyperuricemia (HUA) have been widely studied in the general population but rarely in patients with bipolar disorder (BPD) co-morbid with HUA. This study attempted to investigate the prevalence of HUA in BPD patients and analyze the associated correlates of HUA. MATERIALS AND METHODS: In this study, 182 outpatients with BPD and 182 healthy controls participated. The demographic and clinical information were collected. The body weight, height, waist circumference (WC), hip circumference (HC), and blood pressure (BP) were measured. The levels of serum uric acid (UA), triglyceride (TG), high-density lipoprotein (HDL-C), and fasting blood glucose (FBG) were also determined. RESULTS: BPD patients had a significantly higher prevalence of HUA (40.7%) compared to healthy controls (30.2%) (χ(2) = 4.335, P = 0.037). The systolic blood pressure (SBP), pulse pressure (PP), FBG, UA, and body mass index (BMI) were higher in the BPD group compared with those in the control group, while the diastolic blood pressure (DBP) and HDL-C level were lower (P < 0.05) in BPD patients. The prevalence of HUA was higher in BPD patients who used antipsychotics combined with mood stabilizers than that in BPD subjects receiving the mood stabilizers alone (P < 0.001). The prevalence of HUA and increased serum UA levels were higher in the manic group (62.1%) than in the depressive (34.3%) or euthymia group (17.0%) (P < 0.001). Additionally, the severity of mania was positively correlated with the UA level (r = 0.410, P < 0.001). There were significant differences in terms of MetS (29.7% vs. 14.8%), BMI, HC, WC, TG, and HDL-C between the HUA and the non-HUA groups (P < 0.05). The unconditional logistic regression analysis revealed that high BMI (OR = 1.210; 95%CI: 1.100–1.331) and high TG level (OR = 1.652; 95%CI: 1.058–2.580) were the major risk factorids for HUA in BPD patients. CONCLUSION: Our study suggests that patients with BPD are prone to metabolic diseases such as HUA. Higher serum levels of TG and high BMI could be associated with HUA development. Clinicians need to regularly monitor and evaluate BPD patients for their serum UA levels, especially for BPD patients with manic/hypomanic episodes and/or under the treatment of antipsychotics combined with mood stabilizers. Frontiers Media S.A. 2022-09-16 /pmc/articles/PMC9523783/ /pubmed/36188459 http://dx.doi.org/10.3389/fnins.2022.998747 Text en Copyright © 2022 Li, Lu, Chen, Huang, Zhou, Li and Ning. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Li, Shuyun Lu, Xiaobing Chen, Xiaodong Huang, Zebin Zhou, Hui Li, Zezhi Ning, Yuping The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder |
title | The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder |
title_full | The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder |
title_fullStr | The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder |
title_full_unstemmed | The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder |
title_short | The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder |
title_sort | prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523783/ https://www.ncbi.nlm.nih.gov/pubmed/36188459 http://dx.doi.org/10.3389/fnins.2022.998747 |
work_keys_str_mv | AT lishuyun theprevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder AT luxiaobing theprevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder AT chenxiaodong theprevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder AT huangzebin theprevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder AT zhouhui theprevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder AT lizezhi theprevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder AT ningyuping theprevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder AT lishuyun prevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder AT luxiaobing prevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder AT chenxiaodong prevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder AT huangzebin prevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder AT zhouhui prevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder AT lizezhi prevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder AT ningyuping prevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder |